Novartis to acquire Excellergy, adding Phase 1 anti-IgE program
Deal brings Exl-111 into Novartis’s allergy portfolio, targeting IgE-driven diseases including food allergy and asthma.
Published 3 Apr 2026
Follow Onyx
LinkedIn Read us in Fortune Subscribe
Novo Nordisk's Awiqli delivers the first once-weekly basal insulin for type 2 diabetes
The first once-weekly basal insulin reaches US patients, cutting injection burden from 365 to 52 per year and demonstrating superior glycaemic control in the ONWARDS program
Published 2 Apr 2026
Twenty-seven years to one drug: How failure defined Cytokinetics before Aficamten
Aficamten delivered Cytokinetics’ first commercial validation, yet the path exposed operational friction, from timing to regulatory fluency.
Published 5 Mar 2026
What are GLP-1 agonists and how valuable are they?
GLP-1 is quickly becoming one of the most famous hormones in the world.
Published 10 Sep 2024
The 3 Biggest Biotech Events in 2025
We expect the attendance for each to be well over 20,000 in 2025.
Published 6 Sep 2024
Blood Diagnostics: 3 Biotechs to Watch
Are these the bloods tests of the future?
Published 2 Sep 2024
